Amneal Pharmaceuticals, Inc. AMRX Accrued Litigation
Accrued Litigation at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LitigationReserveNoncurrent.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s accrued litigation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s accrued litigation?
- Amneal Pharmaceuticals, Inc. (AMRX) reported accrued litigation of $70.02M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s accrued litigation changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s accrued litigation decreased by 4.1% year-over-year, from $72.98M to $70.02M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s accrued litigation?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s accrued litigation has grown at a 5.5% compound annual growth rate (CAGR), from $58M to $71.82M.
- What does accrued litigation mean?
- This metric reflects the estimated financial liability recognized on the balance sheet for ongoing or probable legal proceedings and settlements. It captures the company's current exposure to legal risks and the potential impact of litigation on short-term financial health. Investors track this figure to evaluate the magnitude of contingent liabilities and the potential for future cash outflows related to legal disputes.